Diego A Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a post on X:
“MSI-H/dMMR cancers: biology, impact and therapeutic evolution.
A distinct, immunogenic subtype:
-High ICI sensitivity
-Lynch syndrome link
-Key in CRC, endometrial and more
-Now targeted in early stages too
Histology-agnostic precision at its best.”
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
Authors: Margherita Ambrosini et al.
